Most At-Risk Populations.
We're in their Corner.
ReViral brings together the
experience & passion needed
to transform the treatment of viral infections — starting with RSV. We’re committed to developing antiviral therapies to help the world’s most at-risk populations.
- ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir for Treatment of Respiratory Syncytial Virus Infections in Hospitalized Infants
- ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China